Austin I. Kim

947 total citations
17 papers, 179 citations indexed

About

Austin I. Kim is a scholar working on Pathology and Forensic Medicine, Oncology and Genetics. According to data from OpenAlex, Austin I. Kim has authored 17 papers receiving a total of 179 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Pathology and Forensic Medicine, 9 papers in Oncology and 8 papers in Genetics. Recurrent topics in Austin I. Kim's work include Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and CAR-T cell therapy research (5 papers). Austin I. Kim is often cited by papers focused on Lymphoma Diagnosis and Treatment (9 papers), Chronic Lymphocytic Leukemia Research (8 papers) and CAR-T cell therapy research (5 papers). Austin I. Kim collaborates with scholars based in United States, Japan and Australia. Austin I. Kim's co-authors include Caron A. Jacobson, Jennifer L. Crombie, David C. Fisher, Jennifer R. Brown, Josie Montegaard, Ann S. LaCasce, Svitlana Tyekucheva, Philippe Armand, Matthew S. Davids and Jon Arnason and has published in prestigious journals such as Blood, The Lancet Oncology and British Journal of Haematology.

In The Last Decade

Austin I. Kim

16 papers receiving 177 citations

Peers

Countries citing papers authored by Austin I. Kim

Since Specialization

Citations

This map shows the geographic impact of Austin I. Kim's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Austin I. Kim with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Austin I. Kim more than expected).

Fields of papers citing papers by Austin I. Kim

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Austin I. Kim. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Austin I. Kim. The network helps show where Austin I. Kim may publish in the future.

Co-authorship network of co-authors of Austin I. Kim

This figure shows the co-authorship network connecting the top 25 collaborators of Austin I. Kim. A scholar is included among the top collaborators of Austin I. Kim based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Austin I. Kim. Austin I. Kim is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Subgroup analysis of older patients ≥60 years with diffuse large B-cell lymphoma in the phase 3 POLARIX study 2025 ·Blood Advances ·Bei Hu, Patrick M. Reagan, Laurie H. Sehn, Jeff P. Sharman, Mark Hertzberg, Huilai Zhang, Austin I. Kim, Charles Herbaux, Lysiane Molina, Dai Maruyama, Frank Stenner, (unknown), (unknown), Connie Lee Batlevi, Jamie Hirata, Deniz Şahin, Calvin Lee, (unknown), H. Tilly	3
2	A phase-2 study of pembrolizumab in patients with biologically selected subtypes of relapsed/refractory aggressive lymphomas 2025 ·Leukemia & lymphoma ·Mwanasha H. Merrill, Robert Redd, David C. Fisher, Jeremy S. Abramson, Jeffrey A. Barnes, Jaehyuk Choi, Caron A. Jacobson, Austin I. Kim, Matthew A. Lunning, (unknown), (unknown), (unknown), Philippe Armand, (unknown)	1
3	A Phase 2 Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS) 2024 ·Blood ·Jennifer L. Crombie, Christine E. Ryan, (unknown), Svitlana Tyekucheva, (unknown), (unknown), (unknown), Josie Montegaard, Jacob D. Soumerai, Shruti Bhandari, Jon Arnason, Alvaro J. Alencar, Austin I. Kim, Erin M. Parry, Philippe Armand, David C. Fisher, Jennifer R. Brown, Matthew S. Davids	2
4	A Phase 2 Study of Zanubrutinib and Venetoclax (ZV) in Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) 2024 ·Blood ·Inhye E. Ahn, (unknown), David C. Fisher, Austin I. Kim, (unknown), Jon Arnason, (unknown), (unknown), Heather Walker, (unknown), Stacey M. Fernandes, Svitlana Tyekucheva, Matthew S. Davids, Jennifer R. Brown	0
5	A real-world comparison of commercial-use axicabtagene ciloleucel and lisocabtagene maraleucel in large B-cell lymphoma 2024 ·Blood Advances ·(unknown), David Qualls, Dana C. Matthews, Robert Redd, Christopher G. Sakellis, (unknown), (unknown), (unknown), Philippe Armand, Jennifer L. Crombie, David C. Fisher, Eric D. Jacobsen, Austin I. Kim, Ann S. LaCasce, Reid W. Merryman, Erin M. Parry, Caron A. Jacobson	8
6	Effect of atorvastatin versus placebo on efficacy in patients with diffuse large B-cell lymphoma receiving R-CHOP 2024 ·Leukemia & lymphoma ·(unknown), Marielle Scherrer‐Crosbie, Jeremy S. Abramson, Robert Redd, Hannah Gilman, (unknown), Jessica Wu, (unknown), Donna Neuberg, Ephraim P. Hochberg, Jeffrey A. Barnes, Philippe Armand, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Robb S. Friedman, Ann S. LaCasce, Tomas G. Neilan, Jacob D. Soumerai	3
7	Clinical efficacy and safety of chimeric antigen receptor T‐cell therapy for mantle cell lymphoma with secondary central nervous system involvement 2023 ·British Journal of Haematology ·Christine E. Ryan, Rebecca L. Zon, Robert Redd, David C. Fisher, Roni Shouval, Anita Kumar, Jennifer L. Crombie, Hossein Sadrzadeh, Austin I. Kim, Lakshmi Nayak, Ugonma Chukwueke, Caron A. Jacobson, Matthew J. Frigault, M. Lia Palomba, Philippe Armand, Zachary D. Epstein‐Peterson, Reid W. Merryman	8
8	A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma 2023 ·Blood ·Mwanasha H. Merrill, Parastoo B. Dahi, Robert Redd, (unknown), Yi‐Bin Chen, Zachariah DeFilipp, Alex F. Herrera, David C. Fisher, Ann S. LaCasce, Oreofe O. Odejide, Samuel Y. Ng, Caron A. Jacobson, Reid W. Merryman, Austin I. Kim, Yago Nieto, Craig S. Sauter, Gunjan L. Shah, Jasmine Zain, Philippe Armand, Eric D. Jacobsen	6
9	A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma 2023 ·Blood ·Jennifer L. Crombie, Austin I. Kim, Nancy L. Bartlett, Robert Redd, (unknown), (unknown), (unknown), Oreofe O. Odejide, Reid W. Merryman, Ann S. LaCasce, Caron A. Jacobson, Eric D. Jacobsen, Erin M. Parry, David C. Fisher, Alex F. Herrera, Matthew S. Davids, Margaret A. Shipp, Philippe Armand, Geoffrey Shouse	1
10	Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory (R/R) Chronic Lymphocytic Leukemia (CLL) or Richter's Syndrome (RS) 2022 ·Blood ·Christine E. Ryan, Jennifer L. Crombie, Svitlana Tyekucheva, (unknown), Josie Montegaard, Austin I. Kim, Jacob D. Soumerai, Alvaro J. Alencar, Shruti Bhandari, David C. Fisher, Jennifer R. Brown, Matthew S. Davids	5
11	Prognostic value of minimal residual disease among patients with classical Hodgkin lymphoma undergoing autologous stem cell transplantation 2022 ·Leukemia & lymphoma ·(unknown), Robert Redd, (unknown), (unknown), Jennifer L. Crombie, David C. Fisher, Eric D. Jacobsen, Caron A. Jacobson, Austin I. Kim, Ann S. LaCasce, Oreofe O. Odejide, Parastoo B. Dahi, Yago Nieto, Robin Joyce, Yi‐Bin Chen, (unknown), Ammar Chaudhry, Alex F. Herrera, Philippe Armand, Reid W. Merryman	3
12	Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study 2021 ·The Lancet Oncology ·Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva, Zixu Wang, (unknown), (unknown), Josie Montegaard, (unknown), Matthew Weinstock, Jennifer L. Crombie, Samuel Y. Ng, Austin I. Kim, Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, Jon Arnason, David C. Fisher, Jennifer R. Brown	70
13	Polatuzumab Vedotin for Relapsed/Refractory Aggressive B-cell Lymphoma: A Multicenter Post-marketing Analysis 2020 ·Clinical Lymphoma Myeloma & Leukemia ·Stephen D. Smith, (unknown), (unknown), Matthew Mei, Alex F. Herrera, Allison Winter, Brian T. Hill, Mazyar Shadman, Chaitra S. Ujjani, Ryan C. Lynch, Caron A. Jacobson, Austin I. Kim, Paolo F. Caimi, Filippo Milano, Ajay K. Gopal	15
14	Updated Results from a Phase I/II Study of Duvelisib and Venetoclax in Patients with Relapsed or Refractory CLL/SLL or Richter's Syndrome 2020 ·Blood ·Jennifer L. Crombie, Svitlana Tyekucheva, Zixu Wang, Alexandra Savell, Lisa Brennan, (unknown), Karen Francoeur, Josie Montegaard, Austin I. Kim, Jacob D. Soumerai, Jon Arnason, (unknown), (unknown), David C. Fisher, Jennifer R. Brown, Matthew S. Davids	12
15	Updated Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab (AVO) for Frontline Treatment of Chronic Lymphocytic Leukemia (CLL) 2020 ·Blood ·Matthew S. Davids, Benjamin L. Lampson, Svitlana Tyekucheva, Jennifer L. Crombie, Samuel Y. Ng, Austin I. Kim, Matthew Weinstock, (unknown), (unknown), Josie Montegaard, (unknown), Caron A. Jacobson, Ann S. LaCasce, Philippe Armand, Jon Arnason, David C. Fisher, Jennifer R. Brown	13
16	Preliminary Safety and Efficacy Results from a Phase 2 Study of Acalabrutinib, Venetoclax and Obinutuzumab in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) 2019 ·Blood ·Benjamin L. Lampson, Svitlana Tyekucheva, Jennifer L. Crombie, Austin I. Kim, Reid W. Merryman, (unknown), Josie Montegaard, (unknown), Caron A. Jacobson, Eric D. Jacobsen, Ann S. LaCasce, Jon Arnason, Philippe Armand, David C. Fisher, Jennifer R. Brown, Matthew S. Davids	27
17	Suicide in European Hodgkin Lymphoma Patients 2019 ·HemaSphere ·Austin I. Kim, Helen Goergen, Andreas Engert, Ann S. LaCasce, Louise Maranda, Bruce Barton, Sven Borchmann	2

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact